KI-DX-014

• Description:

  KI-DX-014 is a DDX21 inhibitor with an IC50 of 3.31 μM. KI-DX-014 significantly inhibits the DDX21-RNA interaction and modulates ATPase activity and biomolecular condensate formation. KI-DX-014 reduces the DDX21-dependent release of P-TEFb from the 7SK snRNP complex, inhibits P-TEFb-dependent phosphorylation of the RNA polymerase II CTD, and induces developmental defects in zebrafish embryos. KI-DX-014 can be used for cancers and neurodegenerative disorders research[1].

• UNSPSC:

  12352005

• Target:

  ATP Synthase; DNA/RNA Synthesis

• Related Pathways:

  Cell Cycle/DNA Damage; Membrane Transporter/Ion Channel

• Field of Research:

  Cancer; Neurological Disease

• Purity:

  98.5600

• Solubility:

  DMSO : 100 mg/mL (ultrasonic)

• Smiles:

  COC1=CC=C(C=C1)N2N=CC(CN3CCC(C(O)=O)(C3)N)=C2C

• Molecular Formula:

  C17H22N4O3

• Molecular Weight:

  330.38

• References & Citations:

  [1]Aiba T, et al. Chemical Probe Discovery for DEAD-Box RNA-Binding Protein DDX21 Using Small-Molecule Microarrays. ACS Chem Biol. 2025 Jul 10.

• Shipping Conditions:

  Room Temperature

• Storage Conditions:

  4°C (Powder, sealed storage, away from moisture)

• Scientific Category:

  Reference compound1

• Clinical Information:

  No Development Reported

• CAS Number:

  [1309288-83-2]